Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 27, 2023

SELL
$191.51 - $216.16 $2.33 Million - $2.63 Million
-12,175 Reduced 15.32%
67,298 $14.3 Million
Q2 2023

Aug 07, 2023

BUY
$187.64 - $206.25 $12.7 Million - $13.9 Million
67,572 Added 567.78%
79,473 $15.3 Million
Q1 2023

May 09, 2023

SELL
$127.59 - $203.08 $622,001 - $990,015
-4,875 Reduced 29.06%
11,901 $2.41 Million
Q4 2022

Feb 10, 2023

BUY
$117.37 - $139.17 $295,185 - $350,012
2,515 Added 17.64%
16,776 $2.16 Million
Q3 2022

Nov 14, 2022

BUY
$135.27 - $180.11 $1.93 Million - $2.57 Million
14,261 New
14,261 $1.95 Million
Q2 2022

Aug 08, 2022

SELL
$108.81 - $179.33 $225,019 - $370,854
-2,068 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$119.61 - $157.85 $681,777 - $899,745
-5,700 Reduced 73.38%
2,068 $298,000
Q4 2021

Feb 11, 2022

BUY
$142.57 - $190.86 $650,974 - $871,466
4,566 Added 142.6%
7,768 $1.2 Million
Q3 2021

Nov 02, 2021

BUY
$142.45 - $169.82 $284 - $339
2 Added 0.06%
3,202 $544,000
Q2 2021

Aug 13, 2021

BUY
$135.08 - $161.1 $432,256 - $515,520
3,200 New
3,200 $505,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Ing Groep Nv Portfolio

Follow Ing Groep Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

News

Stay updated on Ing Groep Nv with notifications on news.